Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Removed sponsor/investigator identifiers and a drug description line, along with the attribution note, diminishing attribution and navigational context on the study's details page.
    Difference
    0.2%
    Check dated 2026-06-19T21:38:45.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The study record text adds investigator-related items and navigation sections (including Andrea Ardizzoni and several help/section labels) and updates the revision to v3.6.0, while removing the previous attribution and the older Intervention / Treatment label.
    Difference
    1%
    Check dated 2026-06-12T14:24:45.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page revision was updated to v3.5.5, indicating a minor maintenance update to the study details page.
    Difference
    0.0%
    Check dated 2026-06-05T10:27:26.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    A CABOSUN trial reference was added to the Publications section, and the previous erratum citation along with its revision tag (v3.5.3) was removed; this represents a bibliographic update to sources cited on the page.
    Difference
    0.1%
    Check dated 2026-05-14T23:01:27.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.3, replacing Revision: v3.5.2. This indicates a minor update to the page's build/version metadata rather than a change to visible content.
    Difference
    0.0%
    Check dated 2026-04-30T15:29:14.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    Added Cabozantinib Versus Sunitinib as Initial Targeted Therapy publication (CABOSUN trial) citation in Publications and removed the prior CABOSUN entry (revision v3.5.0).
    Difference
    0.1%
    Check dated 2026-04-16T11:00:38.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.